Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer: Economic evaluation in an Italian NHS setting

Clinical Drug Investigation

Volumn 28, Issue 10, 2008, Pages 645-655

  Di Costanzo, Francesco ^a   Ravasio, Roberto ^b   Sobrero, Alberto ^c   Bertetto, Oscar ^d   Vinante, Orazio ^e   Luppi, Gabriele ^f   Labianca, Roberto ^g   Amadori, Dino ^h   Barone, Carlo ⁱ   Merlano, Marco Carlo ^j   Longo, Flavia ^k   Mansueto, Giovanni ^l   Antonuzzo, Lorenzo ^a   Gasperoni, Silvia ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b Wolters Kluwer Health/ADIS International   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d MOLINETTE HOSPITAL   (Italy)

^e USL 17 Ospedale Civile   (Italy)

^f UNIVERSITY HOSPITAL OF TRIESTE   (Italy)

^g OSPEDALI RIUNITI   (Italy)

^h DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

ⁱ CATHOLIC UNIVERSITY   (Italy)

^j Azienda Ospedale S Cuore   (Italy)

^k POLICLINICO UMBERTO I   (Italy)

^l Divisione di Medicina Interna   (Italy)

more..

Author keywords

Capecitabine, therapeutic use; Colon cancer; Cost effectiveness; Fluorouracil, therapeutic use; Folinic acid, therapeutic use

Indexed keywords

AMPHOTERICIN B; CAPECITABINE; CEFALEXIN; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; DOMPERIDONE; E 45; EMOLLIENT AGENT; FLUCONAZOLE; FLUOROURACIL; FOLINIC ACID; GENTAMICIN; LEVOFLOXACIN; LOPERAMIDE; LORAZEPAM; METOCLOPRAMIDE; NYSTATIN; OCTREOTIDE; ONDANSETRON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BOLUS INJECTION; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ECONOMIC EVALUATION; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HISTOPATHOLOGY; HOSPITALIZATION; HUMAN; ITALY; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NATIONAL HEALTH SERVICE; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 51649096852     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200828100-00005     Document Type: Article

References (23)

1. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345: 939-44
2. de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997; 1: 808-15
3. Van Cutsem E, Hoff P, Harper P, et al. Oral capecitabine versus intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004; 90: 1190-7
4. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696-704
5. Scheithauer W, McKendrick J, Begbie S, et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 2003; 14: 1735-43
6. National Institute for Health and Clinical Excellence [online]. Available from URL: http://www.nice.org.ukhttp://www.nice.org.uk/nicemedia/pdf/ TA094guidance.pdf [Accessed 2008 Aug 1]
7. Cassidy J, Douillard J-Y, Twelves C, et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU+LV in Dukes' C colon cancer: the X-ACT trial. Br J Cancer 2006; 94: 1122-9
8. Collett D. Modelling survival data in medical research. London: Chapman & Hall, 1994: 107-49
9. Ramsey S, Andersen MR, Etzioni R, et al. Quality of life in survivors of colorectal carcinoma. Cancer 2000; 88: 1294-303
10. Milano: L'informatore farmaceutico. Milano: OEMF 2005 [online]. Available from URL: http://www.informatorefarmaceutico.it [Accessed 2008 Aug 1]
11. Regione Lombardia. Aggiornamento delle tariffe delle prestazioni ospedaliere in regime di ricovero e attuazione del punto 3 del dispositivo della d.g.r. n. VI/34437 del 4 febbraio 1998
12. Lucioni C, Garancini MP, Massi-Benedetti M, et al. The social cost of type 2 diabetes in Italy: the CODE-2 study [in Italian]. PharmacoEcon Ital Res Artic 2000; 2 (1): 1-21
13. Ministero della salute. Prestazioni di assistenza specialistica ambulatoriale erogabili nell'ambito del Servizio Sanitario Nazionale e relative tariffe. Decreto Ministeriale 22 luglio 1996, Supplemento ordinario alla Gazzetta Ufficiale n.216 del 14 settembre 1996
14. Data on file. Monza: Roche SpA
15. Drummond MF, O'Brien BJ, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 2005
16. Andre T, Colin P, Louvet C, et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 2003; 21: 2896-903
17. Andre T, Quinaux E, Louvet C, et al. Updated results at 6 year of the GERCOR C96.1 phase III study comparing LV5FU2 to monthly 5FU-leucovorin (mFufol) as adjuvant treatment for Dukes B2 and C colon cancer patients [abstract]. J Clin Oncol 2005; 23: 3522
18. Chau I, Norman AR, Cunningham D, et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 2005; 16: 549-57
19. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-14
20. De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47
21. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 1004; 350: 2343-51
22. Wolmark N, Wieand HS, Kuebler JP, et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP Protocol C-07 [abstract no. 3500]. J Clin Oncol 2005; 23: 246s
23. Schmoll H-J, Cartwright T, Tabernero J, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 2007; 25 (1): 102-9